Loading provider…
Loading provider…
Neurology Physician in New York, NY
NPI: 1538256615Primary Practice Location
NEW YORK-PRESBYTERIAN HOSPITAL
5141 Broadway, New York, NY
Primary Employer
Weill Medical College of Cornell
med.cornell.edu
HQ Phone
Get MD Michael's Phone Numberphone_androidMobile
Get MD Michael's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardNY State Medical License
University of California (San Francisco) School of Medicine
Medical School
Until 1992
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99215Established patient office or other outpatient, visit typically 40 minutes | 354 | 485 |
| 2 | 99214Established patient office or other outpatient visit, 30-39 minutes | 269 | 339 |
| 3 | 99205New patient office or other outpatient visit, typically 60 minutes | 177 | 177 |
| 4 | 99213Established patient office or other outpatient visit, typically 15 minutes | 41 | 43 |
| 5 | 99443Physician telephone patient service, 21-30 minutes of medical discussion | 22 | 23 |
Detecting Non-cognitive Features of Prodromal Neurodegenerative Diseases.
Authors: Richard Isaacson, Chin Shun Shih
Journal: Curr Aging Sci
Mitochondrial DNA from platelets of sporadic ALS patients restores normal respiratory functions in ρ0 cells
Authors: Carl D. Gajewski, Michael T. Lin, Merit Cudkowicz, M. Flint Beal, Giovanni Manfredi
Publication Date: 2003-02
Somatic mitochondrial DNA mutations in cortex and substantia nigra in aging and Parkinson's disease.
Authors: David Simon
Journal: Neurobiol Aging
Lead Sponsor: Eli Lilly and Company
Collaborators: Alzheimer's Therapeutic Research Institute
Intervention / Treatment: DRUG: Placebo, DRUG: Solanezumab
Lead Sponsor: Eli Lilly and Company
Intervention / Treatment: DRUG: Lebrikizumab
Lead Sponsor: Eli Lilly and Company
Intervention / Treatment: DRUG: Lebrikizumab